文献速递泌尿系结石

TORADOL 减少输尿管镜症状试验(TRUST)

Toradol to Reduce Ureteroscopy Symptoms Trial (TRUST).
PubMed 文献 · Urology · 2022-03-18

这项随机双盲试验评估了输尿管镜碎石术中静脉注射酮咯酸对围手术期吗啡毫克当量(MME)需求的影响。共分析94例患者,术中给予酮咯酸组术中及围手术期总MME均低于对照组,术后MME无显著差异,并发症无显著差异。

要点

  • 术中静脉注射酮咯酸可降低输尿管镜碎石术患者的术中及围手术期阿片类药物需求。
  • 酮咯酸组术中MME为17.1,对照组为24(P<.01);围手术期总MME为22.2 vs 30.4(P<.02)。
  • 两组术后MME需求及并发症数量无统计学显著差异。

核心结论

  • 输尿管镜术中使用酮咯酸与麻醉药品需求减少37%相关,且是多变量分析中围手术期麻醉药品需求降低的独立预测因素。
  • 作者认为术中 use 酮咯酸可有效减少麻醉药品需求,除非有禁忌,否则应考虑单独使用或作为多模式疼痛控制方案的一部分。

研究设计与样本

  • 随机双盲试验,患者接受门诊输尿管镜治疗肾结石,随机分为麻醉诱导时接受酮咯酸组和对照组,患者与外科医生均设盲。
  • 共分析94例患者,治疗组46例,对照组48例。

主要发现

  • 治疗组术中MME低于对照组(17.1 vs 24,P<.01)。
  • 两组术后MME需求无统计学显著差异。
  • 治疗组围手术期总MME低于对照组(22.2 vs 30.4,P<.02)。
  • 多变量分析中酮咯酸使用是较低MME用量的独立预测因素(beta系数-5.1,P<.01)。
  • 两组并发症数量无统计学显著差异。

临床怎么用

  • 作者认为,除非有禁忌,术中 use 酮咯酸可单独使用或作为多模式疼痛控制方案的一部分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the use of intraoperative IV ketorolac (Toradol) on the peri-operative total morphine milligram equivalent (MME) requirements of patients undergoing ureteroscopy for nephrolithiasis. METHODS: Patients undergoing ambulatory ureteroscopy for nephrolithiasis were randomized to receive ketorolac at time of anesthesia induction. Patients and surgeons were blinded to treatment. Intraoperative, postoperative and combined MME were calculated. Multivariable regression was used to identify independent predictors of MME requirement. Complications were recorded. RESULTS: A total of 94 patients were analyzed following randomization. There were 46 patients in the treatment arm and 48 patients in the control arm. There were no statistically significant differences in gender, age, BMI, operative length or baseline pain medication use between groups (P >.05). Patients in the treatment arm required lower intraoperative MME when compared to the control arm (17.1 vs 24, P< .01). There were no statistically significant differences in the postoperative MME requirements between groups. The combined peri-operative MME was lower in the treatment arm compared to the control arm (22.2 vs 30.4, P< .02). Ketorolac use was an independent predictor of lower MME use on multivariable analysis (beta coefficient -5.1, P< .01). There was no statistically significant difference with regards to complication numbers between the treatment arms. CONCLUSION: Ketorolac during ureteroscopy is associated with a 37% reduction in narcotic requirement and is an independent predictor of decreased peri-operative narcotic needs. These findings show that intra-operative use of ketorolac effectively reduces narcotic requirements and should be considered independently or as part of a multimodal pain control protocol, unless otherwise contraindicated.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Syed JS, Khan A, Van-Ryn MG, et al. Toradol to Reduce Ureteroscopy Symptoms Trial (TRUST). Urology. 2022. PMID: 35314184. doi:10.1016/j.urology.2022.01.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。